Engy Mossad Aboelnaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Engy Mossad Aboelnaga has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Amir M. Zaid
Department of Surgical Oncology, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
4 shared publicationsIslam H. Metwally
Department of Surgical Oncology, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publications- Amal Halim
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 shared publications Mohamed Abdelkhalek
Surgical Oncology Unit, Oncology Center Mansoura University (OCMU), Mansoura, Egypt
2 shared publications- Mohamed M. Aboelnaga
Department of Endocrinology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 shared publications Osama Eldamshety
Department of Surgical Oncology, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 shared publications
Latest Publications
- Open Access
- 1 December 2023
- Published by Egyptian Knowledge Bank in International Journal of Cancer and Biomedical Research
- Vol. 7 (4) , 25-35
Maxillary sinus and hard palate squamous cell carcinoma: Multi-institutional experience
Objectives: To review the clinico-epidemiologic features of maxillary sinus squamous cell carcinoma (MxSSCC) in 2 cancer institutions in our locality with analysis of prognostic factors.Methods: Sixty -four MxSSCC cases were included from January 2000 to June 2018 inclusive. Descriptive and survival analysis were carried out. Cox regression analysis was done to define prognostic factors.Results: The majority of patients were male, smokers, of age range between (40-69years) showing high T staging and high node positivity. The treatment of the primary tumor ranged from surgery +/- adjuvant treatment in 34 patients (53%) , definitive radiotherapy (DRT) +/- chemotherapy; wether induction,concomitant, or both in 25(39%) patients. Neck treatment varied between node dissection +/- radiotherapy (RT) in 25 cases (39.1%), DRT [28 cases (43.7%)], and 6 patients (9.4%) were under wait and watch strategy. The median overall survival (OAS) was 61 months (range: 2-121) and the 5-years OAS was 51.6%. The median progression-free survival (PFS) was 44 months (range: 1-117) and the 5- year PFS was 40.6%. Multivariate analysis of prognostic factors affecting OAS and PFS revealed that low stage and free safety margin were independent positive prognostic factors.Conclusion: Most of cases were presented at a late stage. Surgery +/- adjuvant treatment was the commonest modality for treating the primary tumor, while DRT+/- was used for treating the primary and nodes in nearly 40% of the cases. Low stage and free safety margins were the positive independent prognostic factors. There is a need to investigate stronger treatments for this cancer.
- 1 December 2023
- Published by Egyptian Knowledge Bank in International Journal of Cancer and Biomedical Research
- Vol. 7 (4) , 25-35
Open AccessMaxillary sinus and hard palate squamous cell carcinoma: Multi-institutional experience
Objectives: To review the clinico-epidemiologic features of maxillary sinus squamous cell carcinoma (MxSSCC) in 2 cancer institutions in our locality with analysis of prognostic factors.Methods: Sixty -four MxSSCC cases were included from January 2000 to June 2018 inclusive. Descriptive and survival analysis were carried out. Cox regression analysis was done to define prognostic factors.Results: The majority of patients were male, smokers, of age range between (40-69years) showing high T staging and high node positivity. The treatment of the primary tumor ranged from surgery +/- adjuvant treatment in 34 patients (53%) , definitive radiotherapy (DRT) +/- chemotherapy; wether induction,concomitant, or both in 25(39%) patients. Neck treatment varied between node dissection +/- radiotherapy (RT) in 25 cases (39.1%), DRT [28 cases (43.7%)], and 6 patients (9.4%) were under wait and watch strategy. The median overall survival (OAS) was 61 months (range: 2-121) and the 5-years OAS was 51.6%. The median progression-free survival (PFS) was 44 months (range: 1-117) and the 5- year PFS was 40.6%. Multivariate analysis of prognostic factors affecting OAS and PFS revealed that low stage and free safety margin were independent positive prognostic factors.Conclusion: Most of cases were presented at a late stage. Surgery +/- adjuvant treatment was the commonest modality for treating the primary tumor, while DRT+/- was used for treating the primary and nodes in nearly 40% of the cases. Low stage and free safety margins were the positive independent prognostic factors. There is a need to investigate stronger treatments for this cancer.
- Open Access
- 1 July 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 88 (1) , 2578-2581
Clinico-Epidemiological Study of Maxillary Squamous Cell Carcinoma Cases with Infiltration of The Base of The Skull and/or The Orbit
Background: The most common site of sinonasal and paranasal carcinoma is the maxillary sinus, which accounts for 60-70 percent of all cases. Squamous cell carcinoma (SCC) is the most common histopathological type, accounting for 60–75% . Infiltration of the skull base and/or orbit is one of the complications of such tumours which can have a negative impact on one's quality of life.Objective: The study looked at the epidemiological characteristics and treatment outcomes of patients with maxillary sinus squamous cell carcinoma (MxSSCC) with skull base and/or orbital invasion who were admitted to Mansoura Clinical Oncology and Nuclear Medicine Department and Tanta Clinical Oncology and Nuclear Medicine Department for treatment between January 2000 and December 2018. Patients and methods: This is a retrospective study. Thirteen patient records fulfilled the eligibility criteria of our study. Females were slightly more in number (7 patients (53.8%). The majority of the cases were of age between 40-69 years (N= 11 patients representing 84.6%). Radiotherapy (RT) was the main line of treatment. It was used as the definitive line in ten patients (76.9%) and surgery with postoperative radiotherapy (PORT) was used in (N=3, 23.1%) patients. Results: 5-years overall survival (OAS) of patients with skull base and/or orbital invasion was 15.4% while 2-years progression-free survival (PFS) was 30.8%.Conclusion: This study highlights the effect of the skull base and/or orbital invasion on OAS and PFS of patients with MxSSCC.
- 1 July 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 88 (1) , 2578-2581
Open AccessClinico-Epidemiological Study of Maxillary Squamous Cell Carcinoma Cases with Infiltration of The Base of The Skull and/or The Orbit
Background: The most common site of sinonasal and paranasal carcinoma is the maxillary sinus, which accounts for 60-70 percent of all cases. Squamous cell carcinoma (SCC) is the most common histopathological type, accounting for 60–75% . Infiltration of the skull base and/or orbit is one of the complications of such tumours which can have a negative impact on one's quality of life.Objective: The study looked at the epidemiological characteristics and treatment outcomes of patients with maxillary sinus squamous cell carcinoma (MxSSCC) with skull base and/or orbital invasion who were admitted to Mansoura Clinical Oncology and Nuclear Medicine Department and Tanta Clinical Oncology and Nuclear Medicine Department for treatment between January 2000 and December 2018. Patients and methods: This is a retrospective study. Thirteen patient records fulfilled the eligibility criteria of our study. Females were slightly more in number (7 patients (53.8%). The majority of the cases were of age between 40-69 years (N= 11 patients representing 84.6%). Radiotherapy (RT) was the main line of treatment. It was used as the definitive line in ten patients (76.9%) and surgery with postoperative radiotherapy (PORT) was used in (N=3, 23.1%) patients. Results: 5-years overall survival (OAS) of patients with skull base and/or orbital invasion was 15.4% while 2-years progression-free survival (PFS) was 30.8%.Conclusion: This study highlights the effect of the skull base and/or orbital invasion on OAS and PFS of patients with MxSSCC.
- 1 September 2021
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (5) , 102251
Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes
- 1 September 2021
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (5) , 102251
Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes
- Open Access
- 1 May 2021
- Published by Walter de Gruyter GmbH in Forum of Clinical Oncology
- Vol. 12 (1) , 12-21
Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
Background: A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose. Patients and methods: Patients were enrolled in two groups. Group 1 included 21 patients who received the standard dose of capecitabine (1250 mg/m 2 twice daily [BID] for 14 days), while the patients in group 2 (19 patients) received lower dose of capecitabine (850 mg/m 2 BID for 14 days) every 3 weeks. Results: In group 1, dose reduction was reported in 12 (57.1%) patients versus 1 patient in group 2 (5.3%; P = 0.0005). Patients in group 1 reported higher toxicity rates without any significant difference between the groups. The median duration of response was 17 weeks in group 1, while it was 19 weeks in group 2. Disease progression was recorded in 10 (47.6%) patients in group 1 versus 8 (42.1%) patients in group 2 ( P = 0.81). The mean time to progression was 8.16 ± 0.63 months and the median was 10.1 months in group 1, while the mean was 8.98 ± 0.75 months and the median was 10 months in group 2 ( P = 0.66). The overall survival had a mean of 11.94 ± 0.754 and 11.24 ± 0.665 months, while the median was 13.1 and 13 months in groups 1 and 2, respectively ( P = 0.9). Conclusions: A lower dose of capecitabine provides MBC patients with an active therapy that can be continued for prolonged periods to achieve long-term disease control without compromising its antitumor activity.
- 1 May 2021
- Published by Walter de Gruyter GmbH in Forum of Clinical Oncology
- Vol. 12 (1) , 12-21
Open AccessComparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety
Background: A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose. Patients and methods: Patients were enrolled in two groups. Group 1 included 21 patients who received the standard dose of capecitabine (1250 mg/m 2 twice daily [BID] for 14 days), while the patients in group 2 (19 patients) received lower dose of capecitabine (850 mg/m 2 BID for 14 days) every 3 weeks. Results: In group 1, dose reduction was reported in 12 (57.1%) patients versus 1 patient in group 2 (5.3%; P = 0.0005). Patients in group 1 reported higher toxicity rates without any significant difference between the groups. The median duration of response was 17 weeks in group 1, while it was 19 weeks in group 2. Disease progression was recorded in 10 (47.6%) patients in group 1 versus 8 (42.1%) patients in group 2 ( P = 0.81). The mean time to progression was 8.16 ± 0.63 months and the median was 10.1 months in group 1, while the mean was 8.98 ± 0.75 months and the median was 10 months in group 2 ( P = 0.66). The overall survival had a mean of 11.94 ± 0.754 and 11.24 ± 0.665 months, while the median was 13.1 and 13 months in groups 1 and 2, respectively ( P = 0.9). Conclusions: A lower dose of capecitabine provides MBC patients with an active therapy that can be continued for prolonged periods to achieve long-term disease control without compromising its antitumor activity.
- Open Access
- 6 April 2021
- Published by Springer Nature in Research Square
25-hydroxyvitamin D effect on cancer colon: Is visceral obesity the link?
Background: low 25-hydroxyvitamin have been identified in pathogenesis of colorectal cancer (CRC) with survival affection. Visceral fat tissue predisposes to chronic inflammation and release of growth factors that mediate colonic neoplasia.Aim of the work: to evaluate effect of vitamin D status and visceral obesity on cancer colon and to report the possible link between vitamin D and visceral obesity in those patients. Patients & Methods: Our patients were distributed in two groups; group 1 included cancer colon cases (no= 60) and 2nd group included control cases (no= 40). Clinical, anthropometric and pathological data were collected. Calculation of body mass index, visceral adiposity index (VAI) and detection of Vitamin D (25 OHD) serum level were performed to compare between groups. Results: There were significant differences in VAI and level of 25 OHD between both groups(P=0.011). We found significant higher prevalence of vitamin d deficiency in patient’ group [32 (53.3%) versus control group 13 (32.5%)]. There was a significant lower mean of VAI in vitamin D deficient patients versus non deficient cases (P=0.024). A significant different means of VAI and Vitamin D in patients’ group with different TNM stages. As higher stages associated with lower level of Vitamin D (P=0.027) and higher VAI (P=0.031)Conclusion: The vitamin D may augment the inflammatory status in visceral obesity which reported to be involved in tumourgenesis of cancer colon. Vitamin D deficiency may be a mediator between obesity and cancer and associated with higher tumour stage.
- 6 April 2021
- Published by Springer Nature in Research Square
Open Access25-hydroxyvitamin D effect on cancer colon: Is visceral obesity the link?
Background: low 25-hydroxyvitamin have been identified in pathogenesis of colorectal cancer (CRC) with survival affection. Visceral fat tissue predisposes to chronic inflammation and release of growth factors that mediate colonic neoplasia.Aim of the work: to evaluate effect of vitamin D status and visceral obesity on cancer colon and to report the possible link between vitamin D and visceral obesity in those patients. Patients & Methods: Our patients were distributed in two groups; group 1 included cancer colon cases (no= 60) and 2nd group included control cases (no= 40). Clinical, anthropometric and pathological data were collected. Calculation of body mass index, visceral adiposity index (VAI) and detection of Vitamin D (25 OHD) serum level were performed to compare between groups. Results: There were significant differences in VAI and level of 25 OHD between both groups(P=0.011). We found significant higher prevalence of vitamin d deficiency in patient’ group [32 (53.3%) versus control group 13 (32.5%)]. There was a significant lower mean of VAI in vitamin D deficient patients versus non deficient cases (P=0.024). A significant different means of VAI and Vitamin D in patients’ group with different TNM stages. As higher stages associated with lower level of Vitamin D (P=0.027) and higher VAI (P=0.031)Conclusion: The vitamin D may augment the inflammatory status in visceral obesity which reported to be involved in tumourgenesis of cancer colon. Vitamin D deficiency may be a mediator between obesity and cancer and associated with higher tumour stage.
- 7 November 2020
- Published by Springer Nature in Parasitology Research
- Vol. 120 (4) , 1379-1388
Trichomonas vaginalis serostatus and prostate cancer risk in Egypt: a case-control study
Trichomonas vaginalis is one of the most common non-viral sexually transmitted infections (STIs) that has been associated with prostate cancer in some countries. This study aims to investigate if T. vaginalis infection can be a risk factor for prostate cancer in Egypt and its possible relationship with cancer prognostic factors and overall survival. Serum samples were collected from a total of 445 age-matched males; 126 with prostate cancer, 108 with bladder cancer, 91 with different types of cancers, and 120 healthy controls, and then analyzed by ELISA for detection of anti-Trichomonas IgG and prostate-specific antigen (PSA). The results revealed that only 8.3% of controls were seropositive for trichomoniasis, compared with 19% of prostate cancer patients (P = 0.015). There were positive associations between the levels of PSA and tumor stage with T. vaginalis IgG optical density scores among the seropositive cases (P < 0.001 and < 0.05, respectively). However, no significant correlations were detected between seropositivity of T. vaginalis and other prognostic factors or overall survival in those patients. In conclusion, chronic T. vaginalis infection may be associated with prostate cancer, but it does not seem that this STI aggravates the cancer status.
- 7 November 2020
- Published by Springer Nature in Parasitology Research
- Vol. 120 (4) , 1379-1388
Trichomonas vaginalis serostatus and prostate cancer risk in Egypt: a case-control study
Trichomonas vaginalis is one of the most common non-viral sexually transmitted infections (STIs) that has been associated with prostate cancer in some countries. This study aims to investigate if T. vaginalis infection can be a risk factor for prostate cancer in Egypt and its possible relationship with cancer prognostic factors and overall survival. Serum samples were collected from a total of 445 age-matched males; 126 with prostate cancer, 108 with bladder cancer, 91 with different types of cancers, and 120 healthy controls, and then analyzed by ELISA for detection of anti-Trichomonas IgG and prostate-specific antigen (PSA). The results revealed that only 8.3% of controls were seropositive for trichomoniasis, compared with 19% of prostate cancer patients (P = 0.015). There were positive associations between the levels of PSA and tumor stage with T. vaginalis IgG optical density scores among the seropositive cases (P < 0.001 and < 0.05, respectively). However, no significant correlations were detected between seropositivity of T. vaginalis and other prognostic factors or overall survival in those patients. In conclusion, chronic T. vaginalis infection may be associated with prostate cancer, but it does not seem that this STI aggravates the cancer status.
- 15 July 2020
- Published by Egyptian Knowledge Bank in Research in Oncology
- p. 1
Corrigendum: El-beshbeshi et al. Prognostic Significance of Lymph Node Ratio after Cervical Lymph Node Dissection in Head and Neck Squamous Cell Carcinoma. Res Oncol. 2020; 16(1): 22-30.
This corrigendum corrects the name of the 5th author of this article which was misspelled in the original version as “Entesar Aladl”. The correct spelling is “Entsar Eladl”. The corrected version of the article replaces the primarily published one.
- 15 July 2020
- Published by Egyptian Knowledge Bank in Research in Oncology
- p. 1
Corrigendum: El-beshbeshi et al. Prognostic Significance of Lymph Node Ratio after Cervical Lymph Node Dissection in Head and Neck Squamous Cell Carcinoma. Res Oncol. 2020; 16(1): 22-30.
This corrigendum corrects the name of the 5th author of this article which was misspelled in the original version as “Entesar Aladl”. The correct spelling is “Entsar Eladl”. The corrected version of the article replaces the primarily published one.
- 1 June 2020
- Published by Egyptian Knowledge Bank in Research in Oncology
- Vol. 16 (1) , 22-30
Prognostic Significance of Lymph Node Ratio after Cervical Lymph Node Dissection in Head and Neck Squamous Cell Carcinoma
Background: Lymph node ratio (LNR) is the number of positive lymph nodes (LNs) divided by the total number of excised nodes. It has been shown to be of prognostic significance in a number of cancers. Aim: To investigate the relation between LNR and survival of patients with head and neck squamous cell carcinoma (HNSCC). Methods: A retrospective study of 115 patients with HNSCC treated with curative surgery including neck dissection ± adjuvant treatment from January 2013 to December 2017. Results: The median LNR among node-positive patients was 0.14 which was used as a cutoff point to divide patients into two risk groups. Male gender, N2 stage, high grade and extranodal extension were significantly associated with high (≥0.14) LNR. In multivariate analysis, high LNR, higher TNM nodal stage and larger absolute number of positive LNs associated significantly with worse overall and disease-free survival. In a subgroup analysis of node-positive cases (n=54), LNR associated significantly with disease-free survival but not overall survival. On the other hand, the absolute number of positive LNs and N stage had a significant effect on both overall and disease-free survival. Conclusion: The LNR is of prognostic significance for survival and disease failure in HNSCC. This is also true for the absolute number of positive LNs. Standardization of LN status assessment and determination of an agreed upon cutoff value for LNR are needed before considering its incorporation in the staging system and treatment strategy.
- 1 June 2020
- Published by Egyptian Knowledge Bank in Research in Oncology
- Vol. 16 (1) , 22-30
Prognostic Significance of Lymph Node Ratio after Cervical Lymph Node Dissection in Head and Neck Squamous Cell Carcinoma
Background: Lymph node ratio (LNR) is the number of positive lymph nodes (LNs) divided by the total number of excised nodes. It has been shown to be of prognostic significance in a number of cancers. Aim: To investigate the relation between LNR and survival of patients with head and neck squamous cell carcinoma (HNSCC). Methods: A retrospective study of 115 patients with HNSCC treated with curative surgery including neck dissection ± adjuvant treatment from January 2013 to December 2017. Results: The median LNR among node-positive patients was 0.14 which was used as a cutoff point to divide patients into two risk groups. Male gender, N2 stage, high grade and extranodal extension were significantly associated with high (≥0.14) LNR. In multivariate analysis, high LNR, higher TNM nodal stage and larger absolute number of positive LNs associated significantly with worse overall and disease-free survival. In a subgroup analysis of node-positive cases (n=54), LNR associated significantly with disease-free survival but not overall survival. On the other hand, the absolute number of positive LNs and N stage had a significant effect on both overall and disease-free survival. Conclusion: The LNR is of prognostic significance for survival and disease failure in HNSCC. This is also true for the absolute number of positive LNs. Standardization of LN status assessment and determination of an agreed upon cutoff value for LNR are needed before considering its incorporation in the staging system and treatment strategy.
- 26 May 2020
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 13 (3) , 314-323
Rectal cancer among younger Egyptian patients—clinico-pathological features and oncologic outcomes: A single institution experience
- 26 May 2020
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 13 (3) , 314-323
Rectal cancer among younger Egyptian patients—clinico-pathological features and oncologic outcomes: A single institution experience
- 1 April 2020
- Published by Egyptian Knowledge Bank in Research in Oncology
- p. 1-4
The Impact of Obesity on Surgical Complications and Disease Recurrence in Endometrial Cancer: A Retrospective Study of 267 Patients
Background: Obesity is a well-known risk factor for many health problems including endometrial cancer. In addition, it may act as an obstacle to achieving optimal treatment of endometrial cancer and may be associated with disease recurrence. Aim: To explore the impact of obesity on the operative procedure, recurrence of disease and survival in patients with endometrial cancer. Methods: A retrospective study of 267 patients with endometrial carcinoma who underwent surgery at the Oncology Center-Mansoura University from January 2011 to December 2017. Patients were divided according to their body mass index (BMI) into two groups, Group 1 with a BMI <30 and Group 2 with a BMI ≥30. Results: Group 1 included 46 patients and Group 2 included 221. The mean operative time was longer in Group 2 without statistically significant difference. Twenty-two (47.8%) patients in Group 1 and 71 (32.1%) in Group 2 underwent lymphadenectomy (p = 0.062). The estimated blood loss was significantly higher in Group 2 (p < 0.05). No statistically significant difference was found between the two groups regarding the intra or post-operative complications, despite the high incidence of complications in Group 2. The median disease-free survival (DFS) was 74 months in Group 1 vs. 66 months in Group 2. Obesity did not have a statistically significant impact on DFS among the studied cases (p=0.24). Conclusion: In the current study, obesity did not significantly impact the operative procedure, surgical complications or DFS in patient with endometrial cancer.
- 1 April 2020
- Published by Egyptian Knowledge Bank in Research in Oncology
- p. 1-4
The Impact of Obesity on Surgical Complications and Disease Recurrence in Endometrial Cancer: A Retrospective Study of 267 Patients
Background: Obesity is a well-known risk factor for many health problems including endometrial cancer. In addition, it may act as an obstacle to achieving optimal treatment of endometrial cancer and may be associated with disease recurrence. Aim: To explore the impact of obesity on the operative procedure, recurrence of disease and survival in patients with endometrial cancer. Methods: A retrospective study of 267 patients with endometrial carcinoma who underwent surgery at the Oncology Center-Mansoura University from January 2011 to December 2017. Patients were divided according to their body mass index (BMI) into two groups, Group 1 with a BMI <30 and Group 2 with a BMI ≥30. Results: Group 1 included 46 patients and Group 2 included 221. The mean operative time was longer in Group 2 without statistically significant difference. Twenty-two (47.8%) patients in Group 1 and 71 (32.1%) in Group 2 underwent lymphadenectomy (p = 0.062). The estimated blood loss was significantly higher in Group 2 (p < 0.05). No statistically significant difference was found between the two groups regarding the intra or post-operative complications, despite the high incidence of complications in Group 2. The median disease-free survival (DFS) was 74 months in Group 1 vs. 66 months in Group 2. Obesity did not have a statistically significant impact on DFS among the studied cases (p=0.24). Conclusion: In the current study, obesity did not significantly impact the operative procedure, surgical complications or DFS in patient with endometrial cancer.